Open AccessNeonatal Fc receptor promoter gene polymorphism does not predict pharmacokinetics of IVI g or the clinical course of GBS
Author(s) -
Fokkink WillemJan R.,
Haarman Annechien E. G.,
TioGillen Anne P.,
Rijs Wouter,
Huizinga Ruth,
Doorn Pieter A.,
Jacobs Bart C.
Publication year - 2016
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.307
Subject(s) - medicine , neonatal fc receptor , pharmacokinetics , receptor , antibody , immunology , polymorphism (computer science) , gene , polymerase chain reaction , guillain barre syndrome , immunoglobulin g , pharmacology , genotype , genetics , biology
Treatment of Guillain‐Barré syndrome with a standard course of high‐dose intravenous immunoglobulin ( IVI g) results in a variable clinical recovery which is associated with changes in serum IgG levels after treatment. The neonatal Fc‐receptor protects IgG from degradation, and a genetic polymorphism in its promoter region that influences the expression of Fc‐receptor, may in part explain the variation in IgG levels and outcome. This polymorphism was determined by polymerase chain reaction in a cohort of 257 patients with Guillain‐Barré syndrome treated with IVI g. We could not demonstrate a relation between this polymorphism, the pharmacokinetics of IVI g, or the clinical course and outcome.